井畑 淳 いはた あつし 先生

来歴等

略歴

1993年 横浜市立大学附属病院 研修医
1995年 横浜市立大学医学部内科学第一講座 入局
1999年 三浦市立病院 内科医
2001年 静岡赤十字病院 リウマチ膠原病科 医員
2003年 Food and Drug Administration the Center for Biologics Evaluation & Research
　　　 Laboratory of Retrovirus research. 研究員（Klinman D.M.博士）
2005年 横浜市立大学大学院医学研究科病態免疫制御内科学 助手
2007年 横浜市立大学大学院医学研究科病態免疫制御内科学 助教
2007年 横浜市立大学大学院医学研究科病態免疫制御内科学 学内講師
2013年 横浜市立大学大学院医学研究科病態免疫制御内科学 講師
2013年 国家公務員共済組合連合会 横浜南共済病院 膠原病リウマチ内科 医長
2013年 国家公務員共済組合連合会 横浜南共済病院 リウマチ感染症内科 部長
2016年 国立病院機構横浜医療センター リウマチ科 部長

論文

＜原著＞和文
び漫性増殖性ループス腎炎に対するシクロフォスファミドパルス静注療法の検討/大久保忠信, 出口治子, 井畑淳, 中村満行, 上田敦久, 大野滋, 萩原恵里, 青木昭子, 白井輝, 石ヶ坪良明3/10-リウマチ(40巻3号 :605-611)

全身性自己免疫疾患におけるTh1:Th2バランス異常と,IL-12遺伝子導入による治療の試み/石ヶ坪良明, 萩原恵里, 大久保忠信, 井畑淳, 大野滋, 白井輝, 青木一郎, 奥田研爾4/8-横浜医学(50巻3号 :309-310)

◎レイノー現象の重症度解析におけるレーザードップラーフローサイトメトリーの有用性についての検討/井畑淳1/1-横浜医学(50巻2号 :99-104)

＜原著＞欧文
Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data./Hama M, Takase K, Ihata A, Ueda A, Takeno M, Shizukuishi K, Tateishi U, Ishigatsubo Y.3/8 -Rheumatol Int. (2012;32(5):1327-33.)

Challenges to expanding the clinical application of musculoskeletal ultrasonography (MSUS) among rheumatologists: from a second survey in Japan. /Hama M, Ihata A, Ohno S, Ueda A, Takeno M, Ishigatsubo Y. 2/6-Mod Rheumatol. (2012;22(2):202-8.)

Simultaneous evaluation of long-lasting knee synovitis in patients undergoing arthroplasty by power Doppler ultrasonography and contrast-enhanced MRI in comparison with histopathology. /Takase K, Ohno S, Takeno M, Hama M, Kirino Y, Ihata A, Ideguchi H, Mochida Y, Tateishi U, Shizukuishi K, Nagashima Y, Aoki I, Ishigatsubo Y.6/13 -Clin Exp Rheumatol. (2012;30(1):85-92.)

Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis./Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T, 11/14 Ishigatsubo Y, Miyasaka N, Harigai M; Real Study Group.11/14 -Arthritis Care Res. (2012;64(8):1125-34.)

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. /Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Miyasaka N, Harigai M; for the REAL Study Group.13/16 -Ann Rheum Dis. (2012;71(11):1820-1826.)

Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis./Yoshimi R, Hama M, Ihata A, Ishigatsubo Y.3/4 -Mod Rheumatol. (2012 Jul 18. [Epub ahead of print])

The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis./Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nakajima A, Atsumi T, Yasuda S, Tanaka Y, Saito K, Tohma S, Fujii T, Ihata A, Miyasaka N, Harigai M.13/15 -Mod Rheumatol. (2011;21(4):444-8.)

Neurological manifestations of Behcet's disease in Japan: a study of 54 patients./Ideguchi H, Suda A, Takeno M, Kirino Y, Ihata A, Ueda A, Ohno S, Baba Y, Kuroiwa Y, Ishigatsubo Y.5/10 -J Neurol. (2010 Jun;257(6):1012-20.)

Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells./Ishigatsubo Y, Ihata A, Kobayashi H, Hama M, Kirino Y, Ueda A, Takeno M, Shirai A, Ohno S. 2/9-Mod Rheumatol. (2010 Jun;20(3):263-72.)

Completion rate and compliance of anti-tuberculosis chemoprophylaxis in patients with rheumatic disease receiving tumor necrosis factor antagonists./Ideguchi H, Ohno S, Takase K, Kirino Y, Suda A, Ihata A, Ueda A, Takeno M, Nagaoka S, Ishigatsubo Y.6/10-Clin Exp Rheumatol. (2010 Mar-Apr;28(2):294-5.)

Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis./Murakami S, Takeno M, Kirino Y, Kobayashi M, Watanabe R, Kudo M, Ihata A, Ueda A, Ohno S, Watanuki Y, Kaneko T, Ishigatsubo Y.7/12 -Tuberculosis (Edinb). (2009 Mar;89(2):136-41.)

Association of reduced heme oxygenase-1 with excessive Toll-like receptor 4 expression in peripheral blood mononuclear cells in Behcet's disease./Kirino Y, Takeno M, Watanabe R, Murakami S, Kobayashi M, Ideguchi H, Ihata A, Ohno S, Ueda A, Mizuki N, Ishigatsubo Y.7/11 -Arthritis Res Ther. (2008;10(1))

CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection./Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, Klinman DM.5/6 -J Immunol. (2005 Jan 15;174(2):777-82.)

Contribution of nitric oxide to CpG-mediated protection against Listeria monocytogenes./Ito S, Ishii KJ, Ihata A, Klinman DM.3/4- Infect Immun. (2005 Jun;73(6):3803-5.)

Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene./Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, Yang J, Ishii N, Nakazawa M, Okuda K, Ohnari K, Nakajima K, Xin KQ.2/13-Vaccine. (2001 Jun 14;19(27):3681-91.)

Protection against influenza virus challenge by topical application of influenza DNA vaccine./Watabe S, Xin KQ, Ihata A, Liu LJ, Honsho A, Aoki I, Hamajima K, Wahren B, Okuda K.3/9-Vaccine. (2001 Aug 14;19(31):4434-44.)

IL-12-encoding plasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/lpr mice./Hagiwara E, Okubo T, Aoki I, Ohno S, Tsuji T, Ihata A, Ueda A, Shirai A, Okuda K, Miyazaki J, Ishigatsubo Y. 6/11-Cytokine.(2000 Jul;12(7):1035-41)

Severity of seropositive isolated Raynaud's phenomenon is associated with serological profile./Ihata A, Shirai A, Okubo T, Ohno S, Hagiwara E, Ishigatsubo Y. 1/6-J Rheumatol. (2000 Jul;27(7):1686-92.)

Administration of an IL-12-encoding DNA plasmid prevents the development of chronic graft-versus-host disease (GVHD)./Okubo T, Hagiwara E, Ohno S, Tsuji T, Ihata A, Ueda A, Shirai A, Aoki I, Okuda K, Miyazaki J, Ishigatsubo Y.5/11 -J Immunol. (1999 Apr 1;162(7):4013-7.)

Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1./Ihata A, Watabe S, Sasaki S, Shirai A, Fukushima J, Hamajima K, Inoue J, Okuda K.1/8- Immunology. (1999 Nov;98(3):436-42.)

Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine./Sasaki S, Hamajima K, Fukushima J, Ihata A, Ishii N, Gorai I, Hirahara F, Mohri H, Okuda K.4/9-Infect Immun.(1998 Feb;66(2):823-6.)